Josep Maria Llovet

This study identifies a dietary lipid axis driven by linoleic acid and FADS2 that suppresses antitumor immunity in liver cancer, offering a therapeutic target for immunotherapy resistance.

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.

This study profiles early hepatocellular carcinomas to reveal molecular mechanisms of malignancy transition, identifying TERT alterations, CNA burden, and immune evasion as key factors.

The paper quantifies signalling effects of CTNNB1 mutations across cancer types and finds weakly activating mutations correlate with worse prognosis in hepatocellular carcinoma.

CNApp quantifies genomic copy number alterations in cancer and integrates them with clinical and molecular data to identify clinical implications.

MS.liverK is an R package that implements tools for computing molecular subtypes and functional signatures in liver cancer using transcriptome data.